Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.439 CHF
141.15 M CHF
2.04 B CHF
188.22 M
About BioMarin Pharmaceutical Inc.
Sector
Industry
CEO
Alexander Hardy
Website
Headquarters
San Rafael
Founded
1997
FIGI
BBG00L7CYBG0
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027Yield to maturity
5.11%
Maturity date
May 15, 2027
Explore more bonds
Curated watchlists where BM8 is featured.
Frequently Asked Questions
The current price of BM8 is 59.668 CHF — it has decreased by −20.36% in the past 24 hours. Watch BIOMARIN PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange BIOMARIN PHARMA stocks are traded under the ticker BM8.
We've gathered analysts' opinions on BIOMARIN PHARMA future price: according to them, BM8 price has a max estimate of 113.41 CHF and a min estimate of 58.05 CHF. Watch BM8 chart and read a more detailed BIOMARIN PHARMA stock forecast: see what analysts think of BIOMARIN PHARMA and suggest that you do with its stocks.
BM8 stock is 25.56% volatile and has beta coefficient of 0.32. Track BIOMARIN PHARMA stock price on the chart and check out the list of the most volatile stocks — is BIOMARIN PHARMA there?
Today BIOMARIN PHARMA has the market capitalization of 11.25 B, it has decreased by −2.06% over the last week.
Yes, you can track BIOMARIN PHARMA financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHARMA is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
BM8 earnings for the last quarter are 0.47 CHF per share, whereas the estimation was 0.45 CHF resulting in a 3.59% surprise. The estimated earnings for the next quarter are 0.49 CHF per share. See more details about BIOMARIN PHARMA earnings.
BIOMARIN PHARMA revenue for the last quarter amounts to 631.96 M CHF, despite the estimated figure of 596.11 M CHF. In the next quarter, revenue is expected to reach 639.50 M CHF.
BM8 net income for the last quarter is 89.90 M CHF, while the quarter before that showed 96.35 M CHF of net income which accounts for −6.70% change. Track more BIOMARIN PHARMA financial stats to get the full picture.
No, BM8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 3.40 K employees. See our rating of the largest employees — is BIOMARIN PHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHARMA EBITDA is 415.61 M CHF, and current EBITDA margin is 12.35%. See more stats in BIOMARIN PHARMA financial statements.
Like other stocks, BM8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOMARIN PHARMA technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOMARIN PHARMA stock shows the strong sell signal. See more of BIOMARIN PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.